small Cajal body-specific RNA 18Genealiases: SCARNA18A · U109
Q-omics provides the consensus-scored SCARNA18 profile across patient tissues and cancer cell-line models. SCARNA18 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SCARNA18 is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, SCARNA18 RNA expression shows 12,188 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, STAD, and UVM as cancer lineages where SCARNA18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA18 survival associations across molecular data types. SCARNA18 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA18 RNA expression–survival associations across cancer types. High SCARNA18 expression shows unfavorable associations in KICH, KIRP, UVM, STAD and LIHC, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SCARNA18 RNA expression.
This table summarizes SCARNA18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA18 shows lower tumor expression in KIRC and THCA and higher tumor expression in STAD, BRCA, KICH and COAD. The STAD box plot shows higher SCARNA18 RNA expression in tumor versus normal tissue (log2 FC = +0.349, t-test p = .005).
This table shows molecular features associated with SCARNA18 in patient tissues and cancer cell lines. In patient samples, SCARNA18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
